HTRA1 and coronary artery disorder: Importantly, this model does not imply that damaging variants in HTRA1 cannot cause both clinically manifest cerebrovascular and coronary artery disease; variants that have no proteolytic capacity to any substrate or change expression of HTRA1 would be expected to alter the risk of both pathologies.